2. Search Result
Search Result
Results for "

HDL cholesterol

" in MedChemExpress (MCE) Product Catalog:

32

阻害剤およびアゴニスト

2

生化学アッセイ試薬

7

ペプチド

1

阻害性抗体

1

オリゴヌクレオチド

Targets Recommended:
製品番号 製品名 Target 研究分野 構造式
  • HY-B0388
    Probucol
    2 Publications Verification

    DH-581

    		 Virus Protease Apoptosis Reactive Oxygen Species (ROS) Glutathione Peroxidase Caspase Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Probucol (DH-581) is an anti-hyperlipidemic agent. Probucol activates glutathione peroxidase. Probucol promotes low density lipoprotein (LDL) catabolism, inhibits ABCA1-dependent cholesterol efflux, and decreases HDL-C levels. Probucol also has anti-inflammatory, antioxidant and neuroprotective properties. Probucol can be used for researches on bone, cardiovascular, cancer, neurological, and metabolism-related diseases .
    Probucol
  • HY-134124
    Glutathione ethyl ester

    		Reactive Oxygen Species (ROS) Metabolic Disease
    Glutathione ethyl ester is a cell-permeable GSH donor and provides an efficient supply of GSH to the oocyte. Glutathione ethyl ester shows positive effect on the in vitro production of embryos by enhancement of the antioxidative defense .
    Glutathione ethyl ester
  • HY-12246
    XEN445
    1 Publications Verification

    		 Lipase Cardiovascular Disease Metabolic Disease Cancer
    XEN445 is a potent, selective and orally active endothelial lipase (EL) inhibitor with an IC50 value of 0.237 μM. XEN445 selectively inhibits phospholipase enzymatic activity of LIPG. XEN445 raises plasma HDL and cholesterol levles. XEN445 induces G1 cell cycle arrest, reduces cell viability, suppresses cancer stem cell self-renewal, and inhibits tumor formation in LIPG-expressing triple-negative breast cancer cells, while showing no inhibitory effect on invasiveness or cancer stem cell stemness in these cells. XEN445 can be used for the research of cancer and metabolic disease, such as triple-negative breast cancer .
    XEN445
  • HY-15929
    TBHBA
    1 Publications Verification

    2,4,6-Tribromo-3-hydroxybenzoic acid

    		 Biochemical Assay Reagents Others
    TBHBA (2,4,6-Tribromo-3-hydroxybenzoic acid) is a chemical colorimetric agent and nanomaterial surface modifier. TBHBA can react with some oxidants (such as H2O2) to generate high-absorbance quinoneimine dyes, which enhance the sensitivity of HDL cholesterol enzymatic determination. TBHBA can be used as a bromine-containing coupling agent to modify the surface of silica nanoparticles through esterification reaction. Thereby, organic flame retardant groups are introduced to improve the thermal stability and flame retardant properties of nanocomposites. TBHBA can be used in clinical biochemical testing (such as serum lipoprotein analysis) and the preparation of flame-retardant polymer nanocomposites .
    TBHBA
  • HY-14950
    Dalcetrapib
    2 Publications Verification

    JTT-705; RO4607381

    		 CETP Cardiovascular Disease Cancer
    Dalcetrapib (JTT-705) is an orally active cholesteryl ester transfer protein (CETP) inhibitor with IC50s of 204.6 nM and 6 μM against recombinant human (rh) CETP and human plasma CETP, respectively .
    Dalcetrapib
  • HY-109567
    Gemcabene

    PD-72953

    		 LDLR Metabolic Disease Inflammation/Immunology
    Gemcabene (PD-72953), a first-in-class lipid-lowering agent, lowers low-density lipoprotein cholesterol (LDL-C), decreases triglycerides, and raises high-density lipoprotein cholesterol (HDL-C) and lowers pro-inflammatory acute-phase protein, C-reactive protein (CRP), exerting anti-inflammatory activity .
    Gemcabene
  • HY-P99822
    Recaticimab

    SHR-1209

    		 PCSK9 Metabolic Disease
    Recaticimab (SHR-1209) is a humanized IgG1 mAb that selectively targets PCSK9. Recaticimab reduces low-density lipoprotein cholesterol (LDL-C), non-high-density lipoprotein cholesterol (non-HDL-C), apolipoprotein B (ApoB), triglyceride (TG), and lipoprotein(a) levels. Recaticimab can be used for hyperlipidemia research .
    Recaticimab
  • HY-12089
    Torcetrapib

    CP-529414

    		 CETP Endocrinology
    Torcetrapib (CP-529414) is a selective, potent cholesteryl ester transfer protein (CETP) inhibitor. A typical inhibition curve for whole human plasma, having a CETP concentration of 37 nM .
    Torcetrapib
  • HY-W414588
    Colestolone

    		HMG-CoA Reductase (HMGCR) CETP Metabolic Disease
    Colestolone is a 15-ketosterol compound and an orally active inhibitor of HMG-CoA reductase. Colestolone can inhibit the activity of cholesteryl ester transfer protein (CETP) in vitro (IC50 = 660 μM). Colestolone is a cholesterol-lowering agent, and can be used in the research of endocrine and metabolic diseases such as hyperlipidemia .
    Colestolone
  • HY-121212
    Icosabutate

    		LDLR Metabolic Disease Inflammation/Immunology
    Icosabutate, an orally active ω-3 polyunsaturated fatty acid, is an aeicosapentaenoic acid (EPA) derivative. Icosabutate overcomes the drawbacks of unmodified EPA for liver targeting and improves insulin sensitivity, hepatic inflammation and fibrosis . Icosabutate is well tolerated, and efficacious in lowering non-high-density lipoprotein cholesterol (non-HDL-C) levels in persistent hypertriglyceridemia .
    Icosabutate
  • HY-159709
    VL-422

    		Liposome Metabolic Disease
    VL-422 is an ionizable cationic lipid. VL-422 delivers CRISPR complementary single-guide RNA (sgRNA) and Cas9 mRNA to enable in vitro and in vivo gene editing. LNPs containing VL-422 loaded with Cas9 mRNA and sgRNA targeting the ANGPTL3 gene induce the deletion of premature stop codons within the ANGPTL3 gene in the liver of cynomolgus monkeys. Loss-of-function of ANGPTL3 leads to decreased levels of LDL, HDL and cholesterol in plasma. The VL-422 delivery system can be used for the research of gene editing strategies targeting lipid metabolism diseases .
    VL-422
  • HY-124187
    Pinolenic acid ethyl ester

    Ethyl pinolenate

    		 Biochemical Assay Reagents Others
    Pinolenic acid is a polyunsaturated fatty acid found in the seed oils of red pine (Pinus orientalis) and maritime pine (Pinus pinaster). Both oils were found to have lipid-lowering properties. A diet containing marine pine nut oil (MPSO) reduces HDL and ApoA1 levels in transgenic mice expressing human ApoA1. MPSO was found to reduce cholesterol efflux in vitro. Korean pine nut oil supplements may help obesity by reducing appetite. People who take this oil experience an increase in the satiety hormones CCK and GLP-1 and a decrease in appetite. The activity of the oil is attributed to pinolenic acid. Pinolenic acid is not metabolized to arachidonic acid and can reduce the level of arachidonic acid in the phosphatidylinositol fraction of HepG2 cells from 15.9% to 7.0%. Pinolenic acid ethyl ester is a neutral, more lipophilic form of the free acid.
    Pinolenic acid ethyl ester
  • HY-100902
    CDD3506

    		Cytochrome P450 Metabolic Disease
    CDD3506 is used for elevating high density lipoprotein cholesterol (HDL) by inducing hepatic cytochrome P450IIIA (CYP3A) activity.
    CDD3506
  • HY-107054
    ESP-31015

    ETC-1001

    		 PPAR Cardiovascular Disease
    ESP-31015 (ETC-1001) is an orally active and non-fibrate based PPARα agonists. ESP-31015 demonstrates significant lipid-regulating effects in the obese Zucker rat model. ESP-31015 can be used in cardiovascular disease research .
    ESP-31015
  • HY-176817
    GPR109 receptor agonist-3

    		GPR109A Cardiovascular Disease Metabolic Disease
    GPR109 receptor agonist-3 is an orally active GPR109 receptor agonist, with an IC50 of 310 nM. GPR109 receptor agonist-3 retains the antioxidation and cytoprotection of Lipoic acid (HY-18733). GPR109 receptor agonist-3 reduces total cholesterol (TC), triglyceride (TG), low-density lipoprotein cholesterol (LDL-C) and increases high-density lipoprotein cholesterol (HDL-C) in high-fat diet-fed rats. GPR109 receptor agonist-3 can be used for the study of atherosclerosis .
    GPR109 receptor agonist-3
  • HY-P2424
    Cholecystokinin-J

    CCK-J

    		 Calcium Channel Others
    Cholecystokinin-J (CCK-J), a cholecystokinin, stimulates Ca 2+ release .
    Cholecystokinin-J
  • HY-14950R
    Dalcetrapib (Standard)

    JTT-705 (Standard); RO4607381 (Standard)

    		 CETP Reference Standards Cardiovascular Disease Cancer
    Dalcetrapib (Standard) is the analytical standard of Dalcetrapib. This product is intended for research and analytical applications. Dalcetrapib (JTT-705) is an orally active cholesteryl ester transfer protein (CETP) inhibitor with IC50s of 204.6 nM and 6 μM against recombinant human (rh) CETP and human plasma CETP, respectively .
    Dalcetrapib (Standard)
  • HY-106278A
    GW 590735 sodium

    		PPAR Metabolic Disease
    GW 590735 sodium is a potent and selective PPARα agonist with activity in regulating lipid metabolism. GW 590735 significantly increased high-density lipoprotein (HDL) cholesterol, decreased low-density lipoprotein (LDL) and very low-density lipoprotein (VLDL) cholesterol, and significantly reduced triglycerides. The maximum increases in HDL cholesterol for GW 590735 were 37%, 53% and 84%, respectively, compared with bezafibrate, torcetrapib and GW 590735 .
    GW 590735 sodium
  • HY-100901
    CDD3505

    		Cytochrome P450 Metabolic Disease
    CDD3505 is used for elevating high density lipoprotein cholesterol (HDL) by inducing hepatic cytochrome P450IIIA (CYP3A) activity.
    CDD3505
  • HY-121776
    Nicomol

    		Drug Derivative Cardiovascular Disease
    Nicomol is an orally active hypolipidemic agent that can increase the high density lipoprotein cholesterol (HDL-C) level. Nicomol inhibits the rapid rise of plasma free fatty acids .
    Nicomol
  • HY-115357
    BMS711939

    		PPAR Metabolic Disease
    BMS711939 is a selective agonist for peroxisome proliferator-activated receptor α (PPAR α), with EC50 of 4 nM and 4.5 μM, for human PPARα and human PPARγ. BMS711939 exhibits good pharmacokinetic characters in rats models. BMS711939 increases HDL cholesterol, reduces LDL cholesterol and triglycerides .
    BMS711939
  • HY-121776R
    Nicomol (Standard)

    		Drug Derivative Reference Standards Cardiovascular Disease
    Nicomol (Standard) is the analytical standard of Nicomol. This product is intended for research and analytical applications. Nicomol is an orally active hypolipidemic agent that can increase the high density lipoprotein cholesterol (HDL-C) level. Nicomol inhibits the rapid rise of plasma free fatty acids .
    Nicomol (Standard)
  • HY-109567A
    Gemcabene calcium

    PD-72953 calcium

    		 LDLR Metabolic Disease Inflammation/Immunology
    Gemcabene calcium (PD-72953 calcium), a first-in-class lipid-lowering agent, lowers low-density lipoprotein cholesterol (LDL-C), decreases triglycerides, and raises high-density lipoprotein cholesterol (HDL-C) and lowers pro-inflammatory acute-phase protein, C-reactive protein (CRP), exerting anti-inflammatory activity .
    Gemcabene calcium
  • HY-128338
    CETP-IN-3

    		CETP Cardiovascular Disease
    CETP-IN-3 (Compound 13) is an small molecule inhibitor of the plasma glycoprotein cholesterol ester transfer protein (CETP), elevating HDL-C through inhibition of CETP. CETP-IN-3 for the CETP inhibitory activity in the scintillation proximity (SPA) and whole plasma assay (WPA) with IC50s of 0.002 μM and 0.06 μM, respectively .
    CETP-IN-3
  • HY-P10906
    Talovirtide

    		Biochemical Assay Reagents Others
    Talovirtide is a peptide containing L-valyl .
    Talovirtide
  • HY-P11455
    Lipopeptide CPE4

    		Liposome Others
    Lipopeptide CPE4 is a PEG-modified peptide E4 [(EIAALEK) 4]. Lipopeptide CPE4 is capable of coiled-coil formation when attached to liposomes. Lipopeptide CPE4 triggers membrane fusion between liposomes and living cells with concomitant efficient cytosolic delivery of a variety of compounds such as fluorescent dyes Propidium Iodide (PI) (HY-D0815) and TO-PRO-3 iodide (HY-117070), and Doxorubicin (DOX) (HY-15142A). Lipopeptide CPE4 can be used for drug delivery research .
    Lipopeptide CPE4
  • HY-P10872
    P315V3

    		SARS-CoV Infection
    P315V3 is an pan inhibitor for coronavirus, that inhibits SARS-CoV-2 prototypePT, Delta, BA.1 and BA.4 strain with IC50s of 10.9, 8.9, 8.6, and 2.7 nM. P315V3 exhibits cytotoxicity in Vero cell with CC50 of 4.3 μM. P315V3 exhibits anti-infectious efficacy in mouse models .
    P315V3
  • HY-120433
    BLT-3

    		Scavenger Receptor Class B type I (SR-BI） Inflammation/Immunology
    BLT-3 is an inhibitor of scavenger receptor class B type I (SR-BI) that exerts reversible, non-cell-type-specific inhibitory effects on SR-BI-mediated lipid transport. BLT-3 inhibits SR-BI-mediated selective lipid uptake from HDL as well as cholesterol efflux from cells to HDL. BLT-3 enhances the binding of HDL to SR-BI. BLT-3 is applicable to research related to atherosclerosis and coronary heart disease .
    BLT-3
  • HY-100901R
    CDD3505 (Standard)

    		Cytochrome P450 Reference Standards Metabolic Disease
    CDD3505 (Standard) is the analytical standard of CDD3505 (HY-100901). This product is intended for research and analytical applications. CDD3505 is used for elevating high density lipoprotein cholesterol (HDL) by inducing hepatic cytochrome P450IIIA (CYP3A) activity.
    CDD3505 (Standard)
  • HY-109567R
    Gemcabene (Standard)

    PD-72953 (Standard)

    		 Others Reference Standards Metabolic Disease Inflammation/Immunology
    Gemcabene (Standard) is the analytical standard of Gemcabene. This product is intended for research and analytical applications. Gemcabene (PD-72953), a first-in-class lipid-lowering agent, lowers low-density lipoprotein cholesterol (LDL-C), decreases triglycerides, and raises high-density lipoprotein cholesterol (HDL-C) and lowers pro-inflammatory acute-phase protein, C-reactive protein (CRP), exerting anti-inflammatory activity .
    Gemcabene (Standard)
  • HY-W1126955
    Enlicitide (decanoate)

    MK-0616 (decanoate)

    		 PCSK9 Metabolic Disease Inflammation/Immunology
    Enlicitide (MK-0616) decanoate is an orally active macrocyclic peptide PCSK9 inhibitor. Enlicitide decanoate binds to PCSK9, blocks its interaction with low-density lipoprotein receptor (LDLR), and enhances hepatic clearance of LDL-C. Enlicitide decanoate reduces atherogenic lipoproteins, including non-HDL cholesterol, apolipoprotein B, and lipoprotein (a). Enlicitide decanoate is applicable to research related to hypercholesterolemia, heterozygous familial hypercholesterolemia, and atherosclerotic cardiovascular disease .
    Enlicitide (decanoate)
  • HY-P11766
    GALA-chol

    GALA-cholesterol

    		 Biochemical Assay Reagents Cancer
    GALA-chol is a cholesterol-conjugated pH-responsive fusion peptide that can serve as a delivery adjuvant. GALA-chol enhances the endocytosis of siRNA RET/PTC1-SQ nanoparticles, inhibits cell viability, and undergoes pH-responsive charge conversion in the acidic lysosomal environment, thereby promoting lysosomal escape of small extracellular vesicle (sEV) cargo. GALA-chol anchors to the sEV membrane and maintains the structural integrity and intrinsic homing activity of sEVs. GALA-chol can be used in studies related to adjuvant delivery .
    GALA-chol

オンラインお問い合わせ

入力情報は安全に管理されます. ※ 必須入力項目.

タイトル

  

国或いは地域 *

お名前 *

 

組纖名 *

デパートメント *

     

メールアドレス *

 

製品名 *

製品番号

  

カスタマ需要量 *

電話番号 *

     

必ず会社名を記載ください。個人への返信は行いません。

備考

バルクお問い合わせ

Inquiry Information

製品名:
製品番号:
数量:
MCE 日本正規代理店: